Australian Company Studies the Impact of Rare Cannabinoids on Autism
Neurotech International reported that it is currently working on an open-label Phase I and II clinical study in 20 children aged five to 17 years with Autism Spectrum Disorder (ASD)
Published on 02/11/2026
SAFETY AND TOLERANCE TESTING
Curation and editing by Sechat Content, with information from The GrowthOp
An Australian company with an exclusive license for rare cannabis strains is testing its plants. Neurotech International (NTI) has initiated a study to evaluate the safety and tolerability of its products for treating symptoms associated with autism in children.
In a statement, the company reported that it is currently working on an open-label Phase I and II clinical study in 20 children aged five to 17 years with Autism Spectrum Disorder (ASD).
>>> Follow Sechat on INSTAGRAM
According to the statement, the study marks the first time that full-spectrum cannabis extract containing less than 0.3% THC will be evaluated in children with ASD.
Professor Michael Fahey, head of pediatric neurology at Monash Children's Hospital, is overseeing the tests. They will primarily measure the impact that cannabis has on aspects such as concentration, agitation, irritability, and overall quality of life over 16 weeks.
Specific strains are capable of promoting benefits to autistic children
“Medicinal cannabis has the potential to provide this treatment, but only naturally derived NTI/Dolce strains offer full-spectrum CBDs with little to no THC, an important consideration in treating children,” said Brian Leedman, president of Neurotech.
Above all, NTI strains contain rare cannabinoids, such as CBDP and CBDB, in addition to large amounts of CBD. “This is a new and exciting approach to treating ASD, for which there is a need for safe and effective therapies without side effects that can improve the patient's quality of life,” as Leedman stated.
>>> Join Sechat's group on TELEGRAM and be the first to receive news
In addition to Professor Fahey, clinical behavioral psychologists and older autistic individuals will also be monitoring the results.
According to Catalyst Hunter, NTI is also studying how its cultivars impact attention deficit hyperactivity disorder and epilepsy.
>>> Join Sechat's group on WHATSAPP and be the first to receive news
